These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 31659868

  • 1. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
    Raychaudhuri S, Abria C, Harmany ZT, Smith CM, Kundu-Raychaudhuri S, Raychaudhuri SP, Chaudhari AJ.
    Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
    [Abstract] [Full Text] [Related]

  • 2. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W.
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [Abstract] [Full Text] [Related]

  • 3. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
    Lomonte ABV, Radominski SC, Marcolino FMD, Brenol CV, Zerbini CAF, García EG, Akylbekova EL, Rojo R, de Leon DP.
    Medicine (Baltimore); 2018 Aug; 97(31):e11609. PubMed ID: 30075534
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S, Boy M, Chow V, Chan G.
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [Abstract] [Full Text] [Related]

  • 5. Single- and multiple-dose pharmacokinetics of tofacitinib in healthy Chinese volunteers.
    Krishnaswami S, Wang T, Yuan Y, Alvey CW, Checchio T, Peterson M, Shi H, Riese R.
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):395-9. PubMed ID: 27137149
    [Abstract] [Full Text] [Related]

  • 6. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
    Wei X, Wu J, Zhao G, Galdamez J, Lele SM, Wang X, Liu Y, Soni DM, Purdue PE, Mikuls TR, Goldring SR, Wang D.
    Mol Pharm; 2018 Aug 06; 15(8):3456-3467. PubMed ID: 29966420
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S.
    Arthritis Res Ther; 2016 Jan 28; 18():34. PubMed ID: 26818974
    [Abstract] [Full Text] [Related]

  • 11. [(18)]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis.
    van der Geest T, Metselaar JM, Gerrits D, van Lent PL, Storm G, Laverman P, Boerman OC.
    J Control Release; 2015 Jul 10; 209():20-6. PubMed ID: 25902038
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2.
    Klamerus KJ, Alvey C, Li L, Feng B, Wang R, Kaplan I, Shi H, Dowty ME, Krishnaswami S.
    Clin Pharmacol Drug Dev; 2014 Nov 10; 3(6):499-507. PubMed ID: 27129125
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan 10; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y, Maeshima K, Yamaoka K.
    Ann Rheum Dis; 2012 Apr 10; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
    Fleischmann R.
    Expert Opin Pharmacother; 2017 Oct 10; 18(14):1525-1533. PubMed ID: 28829236
    [Abstract] [Full Text] [Related]

  • 19. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
    Balagué C, Pont M, Prats N, Godessart N.
    Br J Pharmacol; 2012 Jun 10; 166(4):1320-32. PubMed ID: 22229697
    [Abstract] [Full Text] [Related]

  • 20. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
    Tanaka Y, Sugiyama N, Toyoizumi S, Lukic T, Lamba M, Zhang R, Chen C, Stock T, Valdez H, Mojcik C, Fan H, Deng C, Yuasa H.
    Rheumatology (Oxford); 2019 Jan 01; 58(1):70-79. PubMed ID: 30137547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.